About This Research Desk

What Chai Peptides is

Chai Peptides is an independent editorial reference desk covering the published research on three peptides studied through the lens of appetite, satiety, and metabolic-signaling research: MOTS-c, tesamorelin, and tirzepatide, with tirzepatide as the lead. These three compounds do not share a mechanism — one is a mitochondrial-encoded signal, one is a growth-hormone-axis therapy, one is a dual gut-hormone receptor agonist — but each represents a genuinely different way researchers are trying to understand how the body senses fuel, signals fullness, and regulates its own weight.

The desk exists because interest in these compounds — especially online, in research-chemical marketplaces, and in patient communities — regularly outpaces what the underlying literature actually supports. Each compound page tells a reader, in plain language and with citations, what was studied, in whom, using what methods, and how far that evidence honestly reaches. A comparison page lines the three up side by side, and a single shared references list aggregates every source cited across the whole site.

How it is compiled

Three principles govern what appears here. First, every research claim is tied to a numbered citation — peer-reviewed journal articles, clinical-trial publications, regulatory monographs, and clinical-reference chapters, collected with DOIs and PubMed links on the references page. Second, evidence is described at its actual strength: a finding from a 94-person observational cohort is presented as exactly that, not inflated into a general claim, and a compound with zero completed human trials (MOTS-c) is described that way plainly, on every page where it's relevant, rather than glossed over. Third, the compound pages are cross-referenced to one another, because a reader trying to understand any one of these three peptides benefits from seeing how it compares to the others — in mechanism, in evidence maturity, and in regulatory standing.

What it is not

Chai Peptides is not a pharmacy, a clinic, a telehealth platform, or a vendor of any kind. It does not sell, supply, source, or broker any peptide, drug, or research chemical, and it has no affiliate or referral relationship with any manufacturer, telehealth provider, or research-chemical supplier. It does not employ clinicians, diagnose conditions, or prescribe anything, and it does not recommend a dose, schedule, or route of administration for any person, for any of the three compounds covered here — including MOTS-c, for which no established human dosing exists in the literature at all.

Tesamorelin and tirzepatide are approved prescription medicines available only through licensed medical providers, for their specific approved indications. MOTS-c is a research chemical with no approved human use of any kind. Readers seeking clinical guidance should consult a licensed healthcare provider in their own jurisdiction. Editorial correspondence about citations, corrections, or newly published research can be directed to the contact page.